Oral therapy with flurithromycin in ear, nose and throat infections.
In this study efficacy and tolerability of flurithromycin ethylsuccinate (FE) were evaluated in ear, nose and throat infections. One hundred and three patients were treated with FE tablets 375 mg 12-hourly for a mean duration of treatment of 8.2 days and they were divided into groups according to the pathology: pharyngitis/tonsillitis (chronic 7, acute 38), rhinosinusitis (chronic 7, acute 12), otitis (chronic 6, acute 32) and sialadenitis (acute 1). Patients evaluable for clinical efficacy were 101, among them a complete recovery was registered in 88.2%, an improvement in 9.9% and a treatment failure in 1.9%. Bacteriological evaluation was possible in 95 patients, showing the eradication of the pathogen in 94.7%. Tolerability was judged to be excellent in 81.6%, good in 15.5% and discrete in 2.9%. These results demonstrate that FE is safe and effective in the treatment of infections established on acute or chronic inflammatory states.
Galioto
G B
GB
Otorhinolaryngologic Department, Policlinico S. Matteo, University of Pavia, Italy.
Passali
D
D
Catalano
G B
GB
Mevio
E
E
Lepore
A M
AM
Romoli
L
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001774:Blood Chemical Analysis; D004917:Erythromycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007297:Inpatients; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010031:Otitis / Q000188:drug therapy; D010045:Outpatients; D010612:Pharyngitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012793:Sialadenitis / Q000188:drug therapy; D012852:Sinusitis / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy
C045925:flurithromycin; D004917:Erythromycin